1 Min Read NK Cells: First Strike
July 27, 2026NK Cells: First Strike
July 27, 2026
Care Framework & Diagram
NK cells are the immune system's rapid reaction force — they act without waiting for orders
100%
75%
50%
25%
20s
30s
40s
50s
60s
Regular exercisers
Sedentary
THE EVIDENCE
- By 60, regular exercisers show 25–40% higher NK cell activity than sedentary peers.
- Japan cohort (3,600 people, 11 years): the lowest-NK-activity group had significantly higher cancer risk.
Frequently Asked Questions
Both NK cells and T cells can kill cells — what's the difference?
The core difference is recognition mechanism. CD8+ cytotoxic T cells need to 'know' a specific antigen (a specific protein fragment presented on MHC-I) before they can strike — meaning first encounter with a new enemy takes seven to fourteen days to activate. NK cells don't need to recognize any specific antigen in advance; they just need to detect an 'abnormal signal' and act immediately. NK cells are fast but lack specific memory; T cells are slow but precise with memory. Together they form the complete cellular immune defense.
Can NK cells be tested?
Yes. NK cell count and activity testing is part of professional immune function assessment. NK cell count (typically five to twenty percent of peripheral blood lymphocytes) can be measured by flow cytometry; NK cell activity (measuring killing efficiency against standard target cells) is available at specialized immune function testing centers. For healthy individuals, this testing isn't routine — it's more often used for evaluating immune deficiency in those with recurrent infections or for immune monitoring in cancer patients.
What's the relationship between CAR-T therapy and NK cells?
CAR-T (chimeric antigen receptor T cell) therapy uses genetic engineering to give T cells an artificial receptor recognizing specific tumor antigens. Similarly, scientists are developing CAR-NK (chimeric antigen receptor NK cell) therapy. Compared to CAR-T, CAR-NK has several potential advantages: NK cells are universal donor cells (unlike T cells which carry graft-versus-host disease risk), and NK cells already have natural tumor-killing mechanisms. CAR-NK therapy is still in early clinical trials but represents a highly promising direction in cancer immunotherapy.
Are NK cells related to autoimmune diseases?
Yes — in a protective direction. NK cells can maintain immune homeostasis by killing excessively activated T cells (particularly self-reactive T cells attacking the body's own tissue). Research finds that in some autoimmune diseases (lupus, rheumatoid arthritis), NK cell numbers and function are often reduced — which may allow self-reactive T cell activity to go unsuppressed. This connection suggests NK cells also play an important regulatory role in preventing autoimmunity.
